{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:41:03Z","timestamp":1792528863463,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002462","name":"Chungnam National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002462","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Korea Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jchromb.2026.125062","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:59:35Z","timestamp":1775494775000},"page":"125062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Simultaneous LC\u2013MS\/MS method for the quantification of 5-flucytosine, ganciclovir, and valganciclovir to support combined prodrug-activated gene therapy"],"prefix":"10.1016","volume":"1277","author":[{"given":"Yoon Ha","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Jae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Sung","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2026.125062_bb0005","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.ymthe.2021.04.006","article-title":"Prodrugs and prodrug-activated systems in gene therapy","volume":"29","author":"Sheikh","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jchromb.2026.125062_bb0010","first-page":"16849","article-title":"Suicide gene therapy for cancer\u2013current strategies","volume":"4","author":"Zarogoulidis","year":"2013","journal-title":"J. Genet. Syndr. Gene Ther."},{"key":"10.1016\/j.jchromb.2026.125062_bb0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jchromb.2026.125062_bb0020","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/bmc.1326","article-title":"Development and validation of a rapid and sensitive HPLC method for the quantification of 5-fluorocytosine and its metabolites","volume":"24","author":"Serve","year":"2010","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2026.125062_bb0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/cpt1978243333","article-title":"Flucytosine kinetics in subjects with normal and impaired renal function","volume":"24","author":"Cutler","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2026.125062_bb0030","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00003495-199039040-00008","article-title":"Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections","volume":"39","author":"Faulds","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.jchromb.2026.125062_bb0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s13318-014-0200-2","article-title":"Pharmacokinetic studies and LC\u2013MS\/MS method development of ganciclovir and dipeptide monoester prodrugs in Sprague dawley rats","volume":"40","author":"Gunda","year":"2015","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2026.125062_bb0040","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/mcp.2002.126306","article-title":"Pharmacokinetics of valganciclovir and ganciclovir in renal impairment","volume":"72","author":"Czock","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2026.125062_bb0045","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/(SICI)1520-6017(200006)89:6<781::AID-JPS10>3.0.CO;2-7","article-title":"Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PepT1 and PEPT2","volume":"89","author":"Sugawara","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2026.125062_bb0050","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1128\/AAC.44.10.2811-2815.2000","article-title":"Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients","volume":"44","author":"Pescovitz","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2026.125062_bb0055","doi-asserted-by":"crossref","first-page":"615","DOI":"10.5483\/BMBRep.2022.55.12.136","article-title":"Split genome-based retroviral replicating vectors achieve efficient gene delivery and therapeutic effect in a human glioblastoma xenograft model","volume":"55","author":"Kang","year":"2022","journal-title":"BMB Rep."},{"key":"10.1016\/j.jchromb.2026.125062_bb0060","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/14712598.2021.1902982","article-title":"Clinical development of retroviral replicating vector toca 511 for gene therapy of cancer","volume":"21","author":"Collins","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jchromb.2026.125062_bb0065","first-page":"7497","article-title":"Phase i study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer","volume":"63","author":"Freytag","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jchromb.2026.125062_bb0070","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.clinbiochem.2011.04.003","article-title":"Determination of valganciclovir and ganciclovir in human plasma by liquid chromatography tandem mass spectrometric detection","volume":"44","author":"Singh","year":"2011","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jchromb.2026.125062_bb0075","doi-asserted-by":"crossref","first-page":"747","DOI":"10.36468\/pharmaceutical-sciences.566","article-title":"Development and validation of a sensitive and rugged LC-MS\/MS method for evaluation of valganciclovir and its active metabolite ganciclovir in human plasma","volume":"81","author":"Derangula","year":"2019","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2026.125062_bb0080","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0378-4347(96)00518-X","article-title":"Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography: application to a pharmacokinetic study","volume":"692","author":"Joulia","year":"1997","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.jchromb.2026.125062_bb0085","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/jps.20451","article-title":"Comparison of pharmacokinetics of loxoprofen and its active metabolites after an intravenous, intramuscular, and oral administration of loxoprofen in rats: evidence for extrahepatic metabolism","volume":"94","author":"Koo","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2026.125062_bb0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40543-023-00400-6","article-title":"Liquid chromatography-tandem mass spectrometry for pharmacokinetics evaluation of AZD5305, a selective PARP1 inhibitor, in mice","volume":"14","author":"Lee","year":"2023","journal-title":"J. Anal. Sci. Technol."},{"key":"10.1016\/j.jchromb.2026.125062_bb0095","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.3390\/ijms25168760","article-title":"Assessment of dried serum spots (DSS) and volumetric-absorptive microsampling (VAMS) techniques in therapeutic drug monitoring of (val) ganciclovir\u2014comparative study in analytical and clinical practice","volume":"25","author":"Kocur","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jchromb.2026.125062_bb0100","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jchromb.2010.12.033","article-title":"Determination of ganciclovir and its prodrug valganciclovir by hydrophilic interaction liquid chromatography-tandem mass spectrometry","volume":"879","author":"Heinig","year":"2011","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2026.125062_bb0105","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1128\/AAC.48.7.2782-2783.2004","article-title":"Pharmacokinetics of oral valganciclovir and intravenous ganciclovir administered to prevent cytomegalovirus disease in an adult patient receiving small-intestine transplantation","volume":"48","author":"Fort\u00fan Abete","year":"2004","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226001510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226001510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:33:05Z","timestamp":1792528385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023226001510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":21,"alternative-id":["S1570023226001510"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125062","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous LC\u2013MS\/MS method for the quantification of 5-flucytosine, ganciclovir, and valganciclovir to support combined prodrug-activated gene therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125062"}}